logo
Florida is full of expensive restoration projects. Conservation would be cheaper.

Florida is full of expensive restoration projects. Conservation would be cheaper.

Yahoo08-05-2025

A frosted flatwoods salamander, held by a biologist from the Amphibian and Reptile Conservatory.
Before last week, I'd never heard of the frosted flatwoods salamander. Now that I have, I think it's kind of cool. It's a wiggly little amphibian with black-and-white stripes, sort of like if you crossed a zebra with one of those lizards that race across your porch.
These salamanders used to live all over the South. Now they've vanished from most of the places where they once existed.
Fortunately, a group of biologists is trying to ensure the remaining few can hang on to what's left of their Panhandle habitat of slash and longleaf pines.
To help the salamanders stick around, the biologists follow a practice called 'headstarting.' It involves collecting salamander eggs from the wild, hatching them, raising them in places where they're protected from predators, then releasing them once they're larger and have a better chance of survival.
So far this year, they have released 1,204 of these little critters back into the wild. The most recent release was just two weeks ago. That's a lot of salamanders wiggling through the pines.
I talked to the leader of this effort, J.J. Apodaca, a man with an impressively bushy beard and a doctorate in biology. He's the executive director of the Amphibian and Reptile Conservancy, or ARC for short. Any resemblance between this ARC and that ark of Noah's saving two of every species is, I think, entirely intentional.
I asked him why his organization is putting in all this work to save a little salamander that hardly any human knows about.
'We have to keep these species around as part of the ecosystem,' Apodaca told me. 'They have just as much a right to exist as we do.'
The salamanders eat earthworms and spiders and are themselves food for larger animals such as armadillos, he said. I don't plan to lead everyone in singing 'The Circle of Life' from The Lion King, but you can see what would happen to the food chain if the all the salamanders called in sick.
That's why the ARC biologists get down on their hands and knees to look for the salamanders' small, translucent eggs in shallow wetlands near Tallahassee, the home of a LOT of slimy creatures.
Apodaca conceded that the way they're doing this 'would have been considered a radical approach 20 years ago. But we have to intervene in a more radical way to save biodiversity.'
His organization is spending $300,000 a year to save the frosted salamander and its habitat, he said. When I asked if it would have been cheaper to save the species and its home before it became nearly extinct, he said, 'Oh, yeah!' in a tone even more enthusiastic than Kool-Aid Man.
When it comes to conservation versus restoration, conservation is 'vastly more efficient,' he said.
Restoration projects like the one involving the frosted flatwoods salamander are a major industry all over Florida. If I were Ethel Merman, this is where I'd start belting out, 'There's no business like restoration business!'
The biggest example is the Everglades, which has become the largest and most expensive environmental restoration project in human history.
State and federal agencies are spending billions on that one, a project that has already lasted for 25 years and still has a loooong way to go.
But it had to be done, explained Eve Samples, executive director of Friends of the Everglades.
'We've lost more than half the historic Everglades,' said Samples. 'The loss created a huge burden on the public and policymakers to try to restore them.'
The Everglades were once regarded as an obstacle to progress, development, and farming, all of which conspired to get rid of it.
But the River of Grass turned out to be important for the South Florida water supply, the fishing industry, and flood control. That's why we're now spending so much tax money on rebuilding what's left.
Despite the clear lesson of the Everglades, our shortsighted leaders keep allowing the same damage or destruction of other precious parcels of Florida's ecosystems, Samples said.
'There's a painful degree of irony in this,' Samples told me. 'We don't have to keep repeating the same mistakes.'
Another area where lots of our tax dollars are being spent on restoration is the Indian River Lagoon.
The Indian River Lagoon in real life (or 'IRL IRL,' if you're from the texting generation) was once an amazing estuary full of a lot of marine life. Now it's become a graveyard for malnourished manatees.
This happened because the Department of Environmental Protection allowed so much pollution to flow into the lagoon that it stimulated toxic algae blooms. The blooms then killed off the seagrass that the manatees both eat and spread.
As early as 2010, the Save the Manatee Club was warning state officials that the lagoon was going downhill fast, said Pat Rose, the club's longtime executive director.
'We were warning them that the lagoon would soon reach a tipping point and collapse,' Rose told me.
Instead of stepping up efforts to stop the pollution and save the lagoon, government officials let the decline continue until, as had been predicted, the ecosystem collapsed. With nothing to eat, hundreds of manatees starved to death.
State biologists grew so desperate, they tried tossing donated lettuce out in the water, something that had never been tried before.
Now we taxpayers are footing the bill for trying to bring back the seagrass in the lagoon and stop the pollution from messing it up. But Rose said the effort is taking so long — at least 15 years — that he's worried there will be a second collapse and even more manatees will starve.
Just two months ago, Gov. Ron DeSantis announced the state would spend $100 million on trying to fix what's broken in the lagoon. He talked about why the lagoon is important.
'This is the most biologically diverse estuary in all of North America, and it's a key economic driver for the region and the state,' DeSantis said.
Given how important that waterway is, wouldn't it have been smarter — and cheaper — for the DEP to do its job and prevent the pollution in the first place?
'No disagreement there,' Rose said.
Among the experts I called for examples of this phenomenon was Clay Henderson, a longtime preservation advocate who literally wrote the book on the subject ('Forces of Nature'). He mentioned Lake Apopka, once considered the most reliable bass-fishing lake in the South.
'There were over 20 fish camps around the lake,' Jim Peterson of the St. Johns River Water Management District told Spectrum News 13 last year. 'They had lodging, they rented boats, they sold bait, they had entertainment. It was a place to come visit.'
But then farmers were allowed to convert 20,000 acres of marshes on the lake's north shore into dry land for growing row crops.
'They did a great job of growing … but it added a lot of pollution to Lake Apopka,' Peterson told the TV station.
The pollution fueled algae blooms that killed off all the aquatic vegetation (sound familiar?). As a result, the bass fishing declined. Lake Apopka became known as the most polluted lake in the state.
Florida started working on fixing the lake in the 1980s. In 1996, the Legislature approved buying those farms and converting them back into wetlands to help clean up the lake.
Meanwhile, the water district waded into removing the pollutants from the lake. By 2024, the water had become clear enough that 95% of the lake's aquatic vegetation returned.
'The restoration of former muck farms has transformed this area into a haven for wildlife and a jewel for the recreating public,' the water district's website boasts.
To attract anglers back to the lake, the Florida Fish and Wildlife Conservation Commission is stocking it with 1 million largemouth bass.
The cost to the taxpayers for all this: $200 million, spent over four decades.
'Much of the restoration cost was to remediate hazardous waste,' Henderson told me. 'What I've learned over 40 years in conservation is it is always cheaper to buy conservation lands than to restore damaged ecosystems.'
Talking to people about these restoration projects reminded me of a scene from one of my kids' favorite animated movies, 'The Incredibles.'
At the start of the movie, several superheroes sit for interviews. One of them, named Mr. Incredible, complains, 'No matter how many times you save the world, it always manages to get back in jeopardy again. Sometimes I just want it to stay saved, you know, for a little bit?'
We here in Florida know that feeling.
All over the state, we've put in strenuous efforts to save what's best about our state. A lot of acreage has been preserved as state parks and state forests, not to mention the more recent Florida Wildlife Corridor.
The popularity of those programs shows very clearly that people want that land to stay that way — preserved in a natural state.
Yet we've also seen repeated attempts at breaching the wall around the preserves, to un-save what's been saved.
Turns out there are lots of misguided people and politicians who want to build golf courses and big hotels in the parks and roads through the forests and preserves.
'We fight to protect something,' said Cris Costello of the Sierra Club, 'and then we have to be vigilant about protecting it from further threats.'
As a result, the Legislature has just passed a bill to block any further attempt at building golf courses in state parks, something you would think would be obvious. Yet we've now had two governors in a row whose definition of greenspace includes putting greens.
We'll find out soon whether our sitting Duffer-in-Chief, Gov. DeSantis, will sign this bill into law the way he says he will. It's an interesting situation, since the bill is a direct rebuke to his deeply unpopular anti-park moves from last summer.
It never ceases to amaze me how often our elected officials will let developers and other profiteers damage a prime piece of our paradise, make a quick buck, and skedaddle.
Then, and only then, do they figure out that something is broken — usually after a hurricane or some other disaster highlights the flaws. As a result, it's us taxpayers who usually wind up footing the bill.
'Even though the Florida Constitution requires those who cause the pollution to pay the cost of restoration, it's the taxpayers who pay for the clean-up,' Henderson pointed out.
Thus, let me offer a suggestion that's no more radical than 'headstarting' a batch of frosted flatwoods salamanders.
Whenever a developer comes along with grand plans for wiping out wetlands or paving over some other parcel that will hurt the environment, their first step is frequently to ask for the local government to change the zoning on that property.
In other words, they want to build where they shouldn't. I say, if they want to play that way, they should pay for the privilege. I think the local government should require them to put up a bond.
You can call it an impact fee, like the fees that make a developer pay in advance for the new roads, schools, libraries, fire stations, and sewer connections.
Or you could call it something that better describes its purpose: The cost of fixing Florida.
My proposal would be to require every developer who gets a zoning change to post a bond of at least $1 million for every 100 homes to be built.
The bond would need to stay valid for at least a decade. If, during that time, we discover that the houses were built in the wrong place, or are causing problems for the neighbors, or have some other flaw, then the bond could cover the cost of fixing the problem.
That way the taxpayers don't have to bear the burden of repairs. Instead, any money would come out of the pockets of the people who actually caused the problem.
I think we need to hold these rascals to account for the damage they do, because, so far, they've proven to be slipperier than a whole herd of frosted salamanders.
SUPPORT: YOU MAKE OUR WORK POSSIBLE

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Arcus Biosciences presented data for casdatifan plus cabozantinib
Arcus Biosciences presented data for casdatifan plus cabozantinib

Business Insider

time02-06-2025

  • Business Insider

Arcus Biosciences presented data for casdatifan plus cabozantinib

Arcus Biosciences (RCUS) presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Arcus is pursuing a broad development program in both the immuno-oncology-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Confident Investing Starts Here:

Intel says you can download more FPS for Lunar Lake — new driver promises up to 10% higher average frame rates, 25% improvement in 99th percentiles
Intel says you can download more FPS for Lunar Lake — new driver promises up to 10% higher average frame rates, 25% improvement in 99th percentiles

Yahoo

time01-06-2025

  • Yahoo

Intel says you can download more FPS for Lunar Lake — new driver promises up to 10% higher average frame rates, 25% improvement in 99th percentiles

When you buy through links on our articles, Future and its syndication partners may earn a commission. Last month, Intel launched new power-optimized drivers for handheld devices, touting performance gains across various titles. With the latest Arc graphics driver version 32.0.101.6874, Intel is expanding these optimizations to all Core Ultra 200V-powered devices, across laptops and mini-PCs. Since Intel's Arc is still in its early stages, many initial launches have improved with age due to subsequent driver improvements. This has been evident with Alchemist. Furthermore, despite Battlemage offering a relatively stronger and more stable platform at launch, it's clear there is still untapped potential, as shown by these software-driven improvements. Intel's Arc graphics driver 32.0.101.6734 introduced notable low-power mode optimizations for Lunar Lake-powered handhelds, specifically the MSI Claw 8 AI+. After extensive validation and testing, Intel is expanding the scope of these optimizations to all devices, whether laptops or mini-PCs. First-party metrics suggest a 10% bump in performance across the board in nine titles, with the Core Ultra 7 258V at 17W, but your mileage will vary. We'll have to verify these claims through independent testing. It's important to note these improvements are specifically for Intel's low-power Arc 130V and Arc 140V offerings, not the desktop-based Battlemage Arc B-series. The new drivers also address a slew of bugs across various productivity applications and games. A noteworthy detail in the patch notes is the increased memory allocation for integrated Arc GPUs across Core Ultra Series 1 (Meteor Lake) and Series 2 (Arrow Lake and Lunar Lake) product lines, now supporting up to 57% compared to the previous 50% cap. Thus, a 16GB host system can allocate 9.12GB to the iGPU, as opposed to 8GB previously. This isn't the first time Intel has offered improved performance through software updates, as a previous driver release from last October increased FPS by as much as 24%. This builds on earlier optimizations for the Arc platform, so we'll probably see further, likely less pronounced improvements down the road. Most software divisions are likely hard at work preparing the groundwork for next-generation Celestial (Xe3) graphics, set to be introduced with Panther Lake early next year. Follow Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Business Wire

time01-06-2025

  • Business Wire

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 'I was very encouraged to see that nearly half of patients had a confirmed response to the casdatifan plus cabozantinib combination despite short follow-up,' said Toni K. Choueiri, M.D., director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber, the Jerome and Nancy Kohlberg Chair and professor of medicine at Harvard Medical School, and lead investigator of ARC-20. 'Casdatifan plus cabozantinib was well tolerated, and the safety profile was consistent with that of either agent alone, supporting their potential as a combination therapy. I look forward to enrolling patients into the PEAK-1 trial as soon as it is open.' 'The initial data for casdatifan plus cabozantinib in the ARC-20 study have already exceeded the historic benchmarks for either agent alone, as well as that of another HIF-2a inhibitor plus cabozantinib in the same second-line setting,' said Terry Rosen, Ph.D., chief executive officer of Arcus. 'These data serve as the proof of concept for PEAK-1, which will be initiated in the coming weeks and is designed to generate evidence to change the standard of care for people who have progressed on prior immunotherapy treatment.' ARC-20 is a Phase 1/1b dose-escalation and expansion study that includes a cohort evaluating once-daily 100mg of casdatifan plus 60mg of cabozantinib in patients with ccRCC who had progressed on prior immunotherapy. At the time of the data cutoff (DCO, March 14, 2025), 42 participants were evaluable for safety, and 24 reached at least 12 weeks of follow-up and were evaluable for efficacy. Among the safety-evaluable population (N=42), most participants (79%) had an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factor of intermediate or poor. Nearly half (46%) of the efficacy-evaluable population (N=24) achieved a confirmed response per RECIST 1.1, and only one patient had primary progressive disease. The vast majority of the efficacy-evaluable population remains on treatment. In the safety-evaluable population, no unexpected safety risks were identified at the time of DCO, and casdatifan plus cabozantinib had an acceptable safety profile with no meaningful overlapping toxicity for the two drugs. Only two patients discontinued any drug, and no patients discontinued treatment with both drugs. The incidence of treatment-emergent adverse events (TEAEs) with casdatifan, particularly anemia and hypoxia, was similar to TEAEs observed with casdatifan monotherapy, and there were no casdatifan-related Grade 4 or 5 adverse events. The incidence of TEAEs associated with each drug was consistent with what is expected for each drug alone. A summary of the efficacy and safety results is below. Arcus is pursuing a broad development program in both the immuno-oncology (IO)-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Investors may dial in to the conference call at +1 404 975 4839 (local) or +1 833 470 1428 (toll-free) using Conference ID: 446724 on Monday, June 2, 2025, at 5:00 AM PT / 7:00 AM CT. Participants may also register for the call online using the following link: To access the live webcast and accompanying slide presentation, please visit the 'Investors & Media' section of the Arcus Biosciences website at A replay will be available following the live event. About Casdatifan (AB521) Casdatifan is a small-molecule inhibitor of HIF-2a, a transcription factor responsible for activating multiple tumor growth pathways in hypoxic and pseudo-hypoxic tumor environments. By selectively binding HIF-2a, casdatifan is designed to shut down hypoxic oncogenesis and key oncogenic pathways, which leads to cancer cell death. Clear cell renal cell carcinoma is almost universally associated with HIF-2a dysregulation. Casdatifan is currently being evaluated in ARC-20, a Phase 1/1b study in renal cell carcinoma. Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. About RCC According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,980 Americans will be diagnosed with kidney cancer in 2025. Clear cell RCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 18%. In 2022, approximately 32,200 patients with advanced kidney cancer required systemic therapy in the U.S., with over 20,000 patients receiving first-line treatment. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit Forward Looking Statements This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Choueiri's and Dr. Rosen's quotes and statements regarding: the potency, efficacy or safety of casdatifan, including its potential for a best-in-class profile and potential as a combination therapy; and Arcus's development plans for the casdatifan program, including expected timing and design for new studies and cohorts and plans for generating data to support initiation of future studies. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus's actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to risks associated with: interim data not being replicated in future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects with casdatifan; risks associated with manufacturing or supplying product for such clinical trials; uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory application process; difficulties associated with the management of the collaboration activities with our strategic partners or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the 'Risk Factors' section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law. The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store